Metastatic breast cancer: preliminary results with oral hormonal therapy.

abstract：:The current resurgence in the use of nomograms as diagnostic and prognostic tools has legitimate roots in their effectiveness in facilitating communication between the doctor and patient. By returning to a more classical approach to nomography, graphical insights can further enlighten the patient beyond what can be ac...

journal_title：Seminars in oncology

authors： Kattan MW,Marasco J

更新日期：2010-02-01 00:00:00

abstract：:The treatment of locally advanced carcinoma of the cervix with radiation therapy as a single modality is inadequate, specifically for stage III and IVA disease. While chemotherapy as single-modality therapy is ineffective in advanced cervical cancer, there is some evidence of efficacy when used in combination with rad...

journal_title：Seminars in oncology

authors： Wadler S,Goldberg G,Fields A,Anderson P,Beitler JJ,Sood B,Haynes H,Runowicz C

更新日期：1996-08-01 00:00:00

abstract：:Successful allogeneic hematopoietic stem cell transplantation (HSCT) and solid organ transplantation require development of a degree of immune tolerance against allogeneic antigens. T lymphocytes play a critical role in allograft rejection, graft failure, and graft-versus-host disease (GVHD). T-cell tolerance occurs b...

journal_title：Seminars in oncology

authors： Alpdogan O,van den Brink MR

更新日期：2012-12-01 00:00:00

abstract：:A major consequence of administering increasingly aggressive therapies (chemotherapy with or without radiation therapy) in the treatment of non-small cell lung cancer is the adverse effects on the bone marrow that may lead to neutropenia, thrombocytopenia, and/or anemia. Myelosuppression or bone marrow toxicity may al...

journal_title：Seminars in oncology

authors： Ettinger DS

更新日期：2005-04-01 00:00:00

abstract：:This ongoing study was initiated to determine the feasibility of administering amifostine (Ethyol, WR-2721; MedImmune, Inc, Gaithersburg, MD) with monomodal high-dose rate (mHDR) brachytherapy and to assess the tolerability and side effects of this combination. To date, 18 patients suitable for prostate implant brachy...

journal_title：Seminars in oncology

authors： Dziuk T,Senzer N

更新日期：2003-12-01 00:00:00

abstract：:We resected 158 cases of hepatocellular carcinoma (HCC), including 20 (12.6%) cases of large HCC. These 20 cases were divided into group 1 (curative resection, n = 9) and group 2 (noncurative resection, n = 11). The clinicopathologic features and long-term survival of the cases were evaluated. In groups 1 and 2, porta...

journal_title：Seminars in oncology

authors： Noguchi T,Kawarada Y,Kitagawa M,Ito F,Sakurai H,Machishi H,Yamagiwa K,Yokoi H,Mizumoto R

更新日期：1997-04-01 00:00:00

abstract：:In patients with recurrent, previously irradiated head and neck cancer, the traditional therapy of palliative single- or multi-agent chemotherapy yields a 30% to 40% response rate with median survival durations of 8 to 10 months. However, long-term survival is rarely observed. Reirradiation with or without concurrent ...

journal_title：Seminars in oncology

authors： Chmura SJ,Milano MT,Haraf DJ

更新日期：2004-12-01 00:00:00

abstract：:In recent years, several new cytotoxic agents have been investigated for the management of non-small cell lung cancer (NSCLC), including the antimetabolic gemcitabine (Gemzar; Eli Lilly and Company, Indianapolis, IN) and the new multitargeted antifolate pemetrexed (Alimta, Eli Lilly and Company), which are both among ...

journal_title：Seminars in oncology

authors： Le Chevalier T

更新日期：2003-08-01 00:00:00

abstract：:This phase I/II study was done to evaluate the safety and feasibility of two schedules of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) administered by 1-hour infusion in the outpatient setting. Fifty-six patients with advanced, refractory malignancies received one of two paclitaxel schedules by rand...

journal_title：Seminars in oncology

authors： Greco FA,Hainsworth JD

更新日期：1994-10-01 00:00:00

abstract：:In vitro data suggest a synergistic antiproliferative effect of different cytokines. In four clinical studies chronic myelogenous leukemia (CML) patients were treated with interferon (IFN)-alpha alone or IFN-alpha combined with either low-dose IFN-gamma or tumor necrosis factor (TNF)-alpha. The best response was achie...

journal_title：Seminars in oncology

authors： Wandl UB,Opalka B,Kloke O,Nagel-Hiemke M,Moritz T,Niederle N

更新日期：1992-04-01 00:00:00

abstract：:Alterations in chromatin structure resulting from aberrant DNA methylation and perturbations of the histone code profoundly influence gene expression during pulmonary carcinogenesis. Recent studies indicate that DNA demethylating agents and histone deacetylase (HDAC) inhibitors synergistically induce gene expression a...

journal_title：Seminars in oncology

authors： Schrump DS,Nguyen DM

更新日期：2005-10-01 00:00:00

abstract：:Acute lymphoblastic leukemia (ALL) 5-year survival rates are approaching 90% in children and 50% in adults who are receiving contemporary risk-directed treatment protocols. Current efforts focus not only on further improving cure rate but also on patient quality of life. Hence, all protocols decrease or limit the use ...

journal_title：Seminars in oncology

authors： Pui CH,Thiel E

更新日期：2009-08-01 00:00:00

abstract：:For four decades, 5-fluorouracil was the only option available for patients with metastatic colorectal cancer. It provided a response rate of 15% to 20%, with a median survival of approximately 1 year. In the past 5 years, remarkable progress has been made in colorectal cancer research with the approval of irinotecan ...

journal_title：Seminars in oncology

authors： Varadhachary GR,Hoff PM

更新日期：2005-12-01 00:00:00

abstract：:Recent improvements in the management of people living with human immunodeficiency virus (HIV) disease in the United States have led to remarkable reductions in HIV-related morbidity and mortality. The Centers for Disease Control and Prevention recently reported substantial reductions in acquired immunodeficiency synd...

journal_title：Seminars in oncology

authors： Sherer R

更新日期：1998-04-01 00:00:00

abstract：:Most cellular proto-oncogenes encode proteins that participate in signaling pathways by which cells receive and execute instructions that lead to mitogenesis, differentiation, lineage determination, cell migration, extracellular matrix production, and apoptosis, among others. These proto-oncogene protein products incl...

journal_title：Seminars in oncology

authors： Arteaga CL,Khuri F,Krystal G,Sebti S

更新日期：2002-02-01 00:00:00

abstract：:Because patients with metastatic bone disease suffer a significant burden from their illness and from anticancer treatments, it is therefore important to minimize the side effects of bisphosphonates. The intravenous bisphosphonates, zoledronic acid and pamidronate, have tolerability issues that include a flu-like synd...

journal_title：Seminars in oncology

authors： Body JJ,Diel I,Bell R

更新日期：2004-10-01 00:00:00

abstract：:Modulation of the signaling pathways that are aberrant in cancer cells has the potential to provide an effective nontoxic approach to patient management in a broad range of cancers. This quest has taken a major leap forward with the demonstration that STI-571 (imatinib mesylate) induces clinical and molecular remissio...

journal_title：Seminars in oncology

authors： Mills GB,Kohn E,Lu Y,Eder A,Fang X,Wang H,Bast RC,Gray J,Jaffe R,Hortobagyi G

更新日期：2003-10-01 00:00:00

abstract：:The outcome of chemotherapy for patients with stage IV melanoma is unsatisfactory, since durable responses are rarely achieved. More experimental treatments, such as vaccine approaches, antibody treatments, and gene therapy are being developed and are of high scientific interest; however, their efficacy in advanced me...

journal_title：Seminars in oncology

authors： Keilholz U,Gore ME

更新日期：2002-10-01 00:00:00

abstract：:Based on promising results with 5-FU/FA or 5-FU/IFN-alpha in colorectal cancer, a pilot study was initiated to evaluate the effects of the combination 5-FU/FA/interferon alfa (IFN-alpha) in patients with advanced pancreatic cancer. Patients received 9 million units (MU) IFN-alpha subcutaneously three times a week or 6...

journal_title：Seminars in oncology

authors： Knuth A,Bernhard H,Klein O,Meyer zum Büschenfelde KH

更新日期：1992-04-01 00:00:00

abstract：:Among new patients with small cell lung cancer (SCLC), 20% to 25% are over 70 years of age and account for 8,000 cases annually in the United States. For such patients, intensive, aggressive, cytotoxic, combination chemotherapy is not often used because of its association with unacceptable morbidity and mortality rate...

journal_title：Seminars in oncology

authors： Carney DN,Grogan L,Smit EF,Harford P,Berendsen HH,Postmus PE

更新日期：1990-02-01 00:00:00

abstract：:Topotecan (Hycamtin; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) a new chemotherapeutic agent for the treatment of patients with advanced carcinoma of the ovary after failure of initial or subsequent therapy, is a specific, potent inhibitor of the enzyme topoisomerase I. Myelosuppression is the dose-limiting...

journal_title：Seminars in oncology

authors： Saltz L,Janik JE

更新日期：1997-02-01 00:00:00

abstract：:Because studies of breast cancer patients and their relatives provide statistical evidence for involvement of autosomal dominant genes, the identification of specific genetic effects has long been the focus of efforts to identify women at exceedingly high risk. BRCA1, a gene that confers greatly increased susceptibili...

journal_title：Seminars in oncology

authors： Cannon-Albright LA,Skolnick MH

更新日期：1996-02-01 00:00:00

abstract：:At Indiana University, we began clinical trials with ifosfamide in 1981. Although our initial efforts were in a variety of tumor types, including pancreatic cancer, we have most recently focused our attention on two tumors that have historically exhibited a higher degree of chemosensitivity--testicular cancer and smal...

journal_title：Seminars in oncology

authors： Loehrer PJ,Williams SD,Nichols CR,Einhorn LH

更新日期：1992-02-01 00:00:00

abstract：:Cancer cells that express excessive levels of Bcl-2 pose a major problem in the delivery of curative therapy. Most treatments for such cancer involve chemotherapy to induce the apoptotic process. While these therapies often result in disease control for periods of time, failure to initiate apoptosis as a result of acq...

journal_title：Seminars in oncology

authors： Cotter FE

更新日期：2004-12-01 00:00:00

abstract：:Remarkable strides have been made in the management of infectious complications after bone marrow transplantation. Improved understanding of patterns of infection, the introduction of new antimicrobials, the advent of cytokines to enhance immune recovery, the development of better strategies to control graft-versus-ho...

journal_title：Seminars in oncology

authors： Wingard JR

更新日期：1993-10-01 00:00:00

abstract：:The humanized anti-p185(HER2) monoclonal antibody trastuzumab has been shown to effectively inhibit the growth of HER2-overexpressing breast cancer cells in vivo and in vitro. The treatment of cancer cells with trastuzumab results in downregulation of the HER2 receptor. Further downstream cellular events include the a...

journal_title：Seminars in oncology

authors： Baselga J,Albanell J,Molina MA,Arribas J

更新日期：2001-10-01 00:00:00

abstract：:Cisplatin is recognized as an active chemotherapeutic agent in a broad variety of human tumors. The severe emetic effects of cisplatin, however, result in both acute and delayed emesis syndromes causing considerable morbidity. Over the last decade, the standard of therapy for control of cisplatin-induced emesis has be...

journal_title：Seminars in oncology

authors： Perez EA,Hesketh PJ,Gandara DR

更新日期：1991-02-01 00:00:00

abstract：:Capecitabine is an orally administered fluoropyrimidine carbamate that is preferentially converted to 5-fluorouracil in tumors relative to normal tissue. Three different dosing regimens were investigated in phase I studies: continuous monotherapy, intermittent monotherapy, and intermittent therapy supplemented with le...

journal_title：Seminars in oncology

authors： Seitz JF

更新日期：2001-02-01 00:00:00

abstract：:A number of cancers present with synchronous or metachronous hepatic metastases. Historically, many of these patients were considered unresectable and were treated with either systemic chemotherapy or supportive care. Today, a variety of options exist for the management of hepatic metastases. Newer agents for systemic...

journal_title：Seminars in oncology

authors： Arciero CA,Sigurdson ER

更新日期：2008-04-01 00:00:00

abstract：:Over 50% of patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have stage IV disease at presentation and the most likely organ to be affected by metastases is the liver. Hepatic involvement and hepatic tumor burden is a key prognostic factor affecting survival of these patients and 80% eventually di...

journal_title：Seminars in oncology

authors： Keutgen XM,Schadde E,Pommier RF,Halfdanarson TR,Howe JR,Kebebew E

更新日期：2018-08-01 00:00:00